Novartis (VTX:NOVN) received a CHF 84 price objective from JPMorgan Chase & Co. in a research report issued to clients and investors on Thursday. The brokerage currently has a “neutral” rating on the stock. JPMorgan Chase & Co.’s target price suggests a potential downside of 0.10% from the stock’s current price.
NOVN has been the subject of several other reports. set a CHF 90 target price on shares of Novartis and gave the company a “buy” rating in a research note on Tuesday, September 19th. Baader Bank set a CHF 90 target price on shares of Novartis and gave the company a “buy” rating in a research note on Monday, October 30th. Berenberg Bank set a CHF 88 price target on shares of Novartis and gave the company a “neutral” rating in a report on Monday, October 30th. Sanford C. Bernstein set a CHF 97 price target on shares of Novartis and gave the company a “buy” rating in a report on Thursday, October 26th. Finally, Societe Generale set a CHF 95 price target on shares of Novartis and gave the company a “buy” rating in a report on Wednesday, October 25th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of CHF 86.97.
Shares of Novartis (VTX:NOVN) opened at CHF 84.08 on Thursday. Novartis has a one year low of CHF 69.50 and a one year high of CHF 85.40. The stock has a market cap of $219,460.00 and a PE ratio of 30.69.
Novartis Company Profile
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.